- Home
- ADN vs SYBX Comparison
ADN vs SYBX Comparison
Compare ADN & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- SYBX
- Stock Information
- Founded
- ADN 2006
- SYBX N/A
- Country
- ADN United States
- SYBX United States
- Employees
- ADN N/A
- SYBX N/A
- Industry
- ADN Power Generation
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- SYBX Health Care
- Exchange
- ADN Nasdaq
- SYBX Nasdaq
- Market Cap
- ADN 16.7M
- SYBX 16.5M
- IPO Year
- ADN N/A
- SYBX N/A
- Fundamental
- Price
- ADN $6.96
- SYBX $1.46
- Analyst Decision
- ADN
- SYBX Hold
- Analyst Count
- ADN 0
- SYBX 3
- Target Price
- ADN N/A
- SYBX $1.00
- AVG Volume (30 Days)
- ADN 38.3K
- SYBX 25.8K
- Earning Date
- ADN 12-27-2024
- SYBX 11-12-2024
- Dividend Yield
- ADN N/A
- SYBX N/A
- EPS Growth
- ADN N/A
- SYBX N/A
- EPS
- ADN N/A
- SYBX N/A
- Revenue
- ADN $8,157,000.00
- SYBX $2,777,000.00
- Revenue This Year
- ADN $2,232.99
- SYBX N/A
- Revenue Next Year
- ADN $91.56
- SYBX N/A
- P/E Ratio
- ADN N/A
- SYBX N/A
- Revenue Growth
- ADN 274.35
- SYBX 292.23
- 52 Week Low
- ADN $1.71
- SYBX $1.22
- 52 Week High
- ADN $9.54
- SYBX $3.73
- Technical
- Relative Strength Index (RSI)
- ADN 63.08
- SYBX 53.64
- Support Level
- ADN $5.81
- SYBX $1.36
- Resistance Level
- ADN $7.40
- SYBX $1.47
- Average True Range (ATR)
- ADN 0.74
- SYBX 0.08
- MACD
- ADN 0.15
- SYBX 0.00
- Stochastic Oscillator
- ADN 82.33
- SYBX 62.50
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.